In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
Several drugs used for the treatment of colorectal cancer (CRC) are targeted at the epidermal growth factor receptor, but mutations in genes of the RAS family cause resistance to these drugs. Thus, extensive research is being carried out to counterbalance this resistance. The G13D mutation of KRAS is common in humans, and we previously reported that this mutation results in the epigenetic modification of hnRNP proteins, involved in RNA splicing. As aberrant splicing often results in oncogenicity, the present study aimed to identify the genes which show altered splicing patterns in connection with the G13D KRAS mutation. To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS. The in silico results were experimentally validated by quantitative real‑time PCR. Expression of the genes EPDR1 and ZNF518B was negligible in the Caco2, RKO and SW48 cell lines, which possess wild-type KRAS, while the HCT116, DLD1 and D-Mut1 cell lines, harbouring the G13D mutation, expressed these genes. Moreover, in both genes, the ratio of isoforms was significantly different between the parental DLD1 (+/G13D) and D-Mut1 cells, in which the wild-type allele had been knocked out. DWT7m cells also expressed both genes. These cells, derived from DLD1, have spontaneously acquired a G12D mutation in their single KRAS allele in 20% of the population. The present data suggest a relationship between KRAS mutations, particularly G13D, and the expression of the EPDR1 and ZNF518B genes and expression of their isoforms and provide enhanced understanding of the molecular mechanisms involved in the resistance of CRC cells to anti‑EGF receptor therapies.
Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain.
Ángela L
ÁL
Riffo-Campos
INCLIVA Institute of Health Research, Valencia, Spain.
Josefa
J
Castillo
Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain.
Azahara
A
Vallet-Sánchez
Department of Statistics and Operational Research, University of Valencia, Burjassot, Valencia, Spain.
Guillermo
G
Ayala
INCLIVA Institute of Health Research, Valencia, Spain.
Andrés
A
Cervantes
Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain.
Gerardo
G
López-Rodas
Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain.
Luis
L
Franco
D017398:Alternative Splicing; D001483:Base Sequence; D015179:Colorectal Neoplasms / Q000235:genetics*; D003198:Computer Simulation; D004268:DNA-Binding Proteins / Q000235:genetics* / Q000378:metabolism; D015870:Gene Expression; D006801:Humans; D008957:Models, Genetic; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D009419:Nerve Tissue Proteins; D020033:Protein Isoforms / Q000235:genetics / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D017423:Sequence Analysis, RNA; D036341:Intercellular Signaling Peptides and Proteins
D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D009419:Nerve Tissue Proteins; D020033:Protein Isoforms; D016283:Proto-Oncogene Proteins p21(ras); C456603:EPDR1 protein, human; D036341:Intercellular Signaling Peptides and Proteins; C117307:KRAS protein, human; C000608154:ZNF518B protein, human